EBV and systemic lupus erythematosus: A new perspective

Journal of Immunology

Volumn 174, Issue 11, 2005, Pages 6599-6607

  Gross, Andrew J ^a,b   Hochberg, Donna ^a   Rand, William M ^a   Thorley Lawson, David A ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMEDIATE EARLY PROTEIN BZLF1; LATENCY MEMBRANE PROTEIN 1; LATENCY MEMBRANE PROTEIN 2A; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADULT; AGED; B LYMPHOCYTE; CONTROLLED STUDY; DISEASE ACTIVITY; EPSTEIN BARR VIRUS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; MEMORY CELL; PERSISTENT INFECTION; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRUS DETECTION;

EID: 18944396623     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.174.11.6599     Document Type: Review

References (53)

1. Khanna, R., and S. R. Burrows. 2000. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu. Rev. Microbiol. 54: 19-48.
2. + T cells. J. Immunol. 168: 4184-4191.
3. + T cell response to Epstein-Barr virus during primary and persistent infection. J. Exp. Med. 198: 903-911.
4. Hochberg, D., J. M. Middeldorp, M. Catalina, J. L. Sullivan, K. Luzuriaga, and D. A. Thorley-Lawson. 2004. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc. Natl. Acad. Sci. USA 101: 239-244.
5. Thorley-Lawson, D. 2001. Epstein-Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1: 75-82.
6. Thorley-Lawson, D. A., and A. J. Gross. 2004. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N. Engl. J. Med. 350: 1328-1337.
7. Joseph, A. M., G. J. Babcock, and D. A. Thorley-Lawson. 2000. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J. Virol. 74: 9964-9971.
8. Babcock, G. J., D. Hochberg, and A. D. Thorley-Lawson. 2000. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13: 497-506.
9. Babcock, G. J., and D. A. Thorley-Lawson. 2000. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc. Natl. Acad. Sci. USA 97: 12250-12255.
10. Laichalk, L. L., and D. A. Thorley-Lawson. 2005. Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J. Virol. 79: 1296-1307.
11. Hahn, B. 1997. An overview of the pathogenesis of systemic lupus erythematosus. In Dubois' Lupus Erythematosus. D. Wallace and B. Hahn, eds. Williams & Wilkins, Baltimore, p. 69-75.
12. Liossis, S. N., B. Kovacs, G. Dennis, G. M. Kammer, and G. C. Tsokos. 1996. B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J. Clin. Invest. 98: 2549-2557.
13. Arce, E., D. G. Jackson, M. A. Gill, L. B. Bennett, J. Banchereau, and V. Pascual. 2001. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J. Immunol. 167: 2361-2369.
14. Grammer, A. C., R. Slota, R. Fischer, H. Gur, H. Girschick, C. Yarboro, G. G. Illei, and P. E. Lipsky. 2003. Abnormal germinal center reactions in systemic lupus erythematosus demonstrated by blockade of CD154-CD40 interactions. J. Clin. Invest. 112: 1506-1520.
15. Folzenlogen, D., M. F. Hofer, D. Y. Leung, J. H. Freed, and M. K. Newell. 1997. Analysis of CD80 and CD86 expression on peripheral blood B lymphocytes reveals increased expression of CD86 in lupus patients. Clin. Immunol. Immunopathol. 83: 199-204.
16. Huck, S., R. Le Corre, P. Youinou, and M. Zouali. 2001. Expression of B cell receptor-associated signaling molecules in human lupus. Autoimmunity 33: 213-224.
17. Liossis, S. N., E. E. Solomou, M. A. Dimopoulos, P. Panayiotidis, M. M. Mavrikakis, and P. P. Sfikakis. 2001. B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J. Investig. Med. 49: 157-165.
18. Stohl, W., A. S. Hamilton, D. M. Deapen, T. M. Mack, and D. A. Horwitz. 1999. Impaired cytotoxic T lymphocyte activity in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: a contributory role for non-T cells. Lupus 8: 293-299.
19. Kang, I., T. Quan, H. Nolasco, S. H. Park, M. S. Hong, J. Crouch, E. G. Pamer, J. G. Howe, and J. Craft. 2004. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J. Immunol. 172: 1287-1294.
20. Moon, U. Y., S. J. Park, S. T. Oh, W. U. Kim, S. H. Park, S. H. Lee, C. S. Cho, H. Y. Kim, W. K. Lee, and S. K. Lee. 2004. Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res. Ther. 6: R295-R302.
21. Strauch, B., L. L. Andrews, N. Siegel, and G. Miller. 1974. Oropharyngeal excretion of Epstein-Barr virus by renal transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1: 234-237.
22. Bombardier, C., D. D. Gladman, M. B. Urowitz, D. Caron, and C. H. Chang. 1992. Derivation of the SLEDAI: a disease activity index for lupus patients: the Committee on Prognosis Studies in SLE. Arthritis Rheum. 35: 630-640.
23. Petri, M., J. Buyon, and M. Kim. 1999. Classification and definition of major flares in SLE clinical trials. Lupus 8: 685-691.
24. Babcock, G. J., L. L. Decker, M. Volk, and D. A. Thorley-Lawson. 1998. EBV persistence in memory B cells in vivo. Immunity 9: 395-404.
25. Khan, G., E. M. Miyashita, B. Yang, G. J. Babcock, and D. A. Thorley-Lawson. 1996. Is EBV persistence in vivo a model for B cell homeostasis? Immunity 5: 173-179.
26. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1996. A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle. J. Virol. 70: 8204-8208.
27. Chen, F., J. Z. Zou, L. di Renzo, G. Winberg, L. F. Hu, E. Klein, G. Klein, and I. Ernberg. 1995. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69: 3752-3758.
28. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68: 7374-7385.
29. Tanaka, N., H. Kimura, K. Iida, Y. Saito, I. Tsuge, A. Yoshimi, T. Matsuyama, and T. Morishima. 2000. Quantitative analysis of cytomegalovirus load using a real-time PCR assay. J. Med. Virol. 60: 455-462.
30. Miyashita, E. M., B. Yang, K. M. Lam, D. H. Crawford, and D. A. Thorley-Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80: 593-601.
31. Babcock, G. J., L. L. Decker, R. B. Freeman, and D. A. Thorley-Lawson. 1999. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients. J. Exp. Med. 190: 567-576.
32. Odendahl, M., A. Jacobi, A. Hansen, E. Feist, F. Hiepe, G. R. Burmester, P. E. Lipsky, A. Radbruch, and T. Dorner. 2000. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J. Immunol. 165: 5970-5979.
33. Qu, L., M. Green, S. Webber, J. Reyes, D. Ellis, and D. Rowe. 2000. Epstein-Barr virus gene expression in the peripheral blood of transplant recipients with persistent circulating virus loads. J. Infect. Dis. 182: 1013-1021.
34. Rose, C., M. Green, S. Webber, D. Ellis, J. Reyes, and D. Rowe. 2001. Pediatric solid-organ transplant recipients carry chronic loads of Epstein-Barr virus exclusively in the immunoglobulin D-negative B-cell compartment. J. Clin. Microbiol. 39: 1407-1415.
35. Bermas, B. L., M. Petri, D. Goldman, B. Mittleman, M. W. Miller, N. I. Stocks, C. S. Via, and G. M. Shearer. 1994. T helper cell dysfunction in systemic lupus erythematosus (SLE): relation to disease activity. J. Clin. Immunol. 14: 169-177.
36. Kilger, E., A. Kieser, M. Baumann, and W. Hammerschmidt. 1998. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17: 1700-1709.
37. Caldwell, R. G., J. B. Wilson, S. J. Anderson, and R. Longnecker. 1998. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9: 405-411.
38. Zimber-Strobl, U., B. Kempkes, G. Marschall, R. Zeidler, C. Van Kooten, J. Banchereau, G. W. Bornkamm, and W. Hammerschmidt. 1996. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 15: 7070-7078.
39. Miyashita, E. M., B. Yang, G. I. Babcock, and D. A. Thorley-Lawson. 1997. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J. Virol. 71: 4882-4891.
40. Qu, L., and D. T. Rowe. 1992. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. Virol. 66: 3715-3724.
41. Hochberg, D., T. Souza, M. Catalina, J. L. Sullivan, K. Luzuriaga, and D. A. Thorley-Lawson. 2004. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol. 78: 5194-5204.
42. Joseph, A. M., G. J. Babcock, and D. A. Thorley-Lawson. 2000. EBV persistence involves strict selection of latently infected B cells. J. Immunol 165: 2975-2981.
43. James, J. A., K. M. Kaufman, A. D. Farris, E. Taylor-Albert, T. J. Lehman, and J. B. Harley. 1997. An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J. Clin. Invest. 100: 3019-3026.
44. Khanna, R., D. J. Moss, and S. R. Burrows. 1999. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol. Rev. 170: 49-64.
45. Crawford, D. H., J. M. Edwards, P. Sweny, A. V. Hoffbrand, and G. Janossy. 1981. Studies on long-term T-cell-mediated immunity to Epstein-Barr virus in immunosuppressed renal allograft recipients. Int. J. Cancer 28: 705-709.
46. Crawford, D. H., P. Sweny, J. M. Edwards, G. Janossy, and A. V. Hoffbrand. 1981. Long-term T-cell-mediated immunity to Epstein-Barr virus in renal-allograft recipients receiving cyclosporin A. Lancet 1: 10-12.
47. Yao, Q. Y., A. B. Rickinson, J. S. Gaston, and M. A. Epstein. 1985. In vitro analysis of the Epstein-Barr virus: host balance in long-term renal allograft recipients. Int. J. Cancer 35: 43-49.
48. Hopwood, P., and D. H. Crawford. 2000. The role of EBV in post-transplant malignancies: a review. J. Clin. Pathol. 53: 248-254.
49. Kang, I., and S. H. Park. 2003. Infectious complications in SLE after immunosuppressive therapies. Curr. Opin. Rheumatol. 15: 528-534.
50. Kahl, L. E. 1994. Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome. J. Rheumatol. 21: 84-86.
51. Seemayer, T. A., T. G. Gross, R. M. Egeler, S. J. Pirruccello, J. R. Davis, C. M. Kelly, M. Okano, A. Lanyi, and J. Sumegi. 1995. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr. Res. 38: 471-478.
52. Sullivan, J. L., and B. A. Woda. 1989. X-linked lymphoproliferative syndrome. Immunodefic. Rev. 1: 325-347.
53. Purtilo, D. T., C. K. Cassel, J. P. Yang, and R. Harper. 1975. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1: 935-940.